Corcept Therapeutics (CORT): Analyst Says Shares Pricing in Growth, New Launch

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the Stocks That Could Mint Millionaires in 2026.

Corcept Therapeutics (CORT): Analyst Says Shares Pricing in Growth, New Launch

On December 16, UBS analyst Ashwani Verma initiated coverage of Corcept Therapeutics Incorporated (NASDAQ:CORT) stock with a Neutral rating and $95 price target. In an investor note, the analyst cited valuation for the Neutral rating, with the shares up 64% year-to-date. Per the analyst, the stock was already pricing in both the continued growth in hypercortisolism and Corcept’s new launch opportunity in platinum-resistant ovarian cancer.

In early November, the company posted earnings for the third quarter of 2025, reporting earnings per share of $0.16, beating market estimates by $0.02. The revenue over the period was more than $207 million, up close to 14% compared to the revenue over the same period last year and missing analyst expectations by close to $11 million. The firm also modified 2025 revenue guidance of $800 to $850 million versus the $852 million consensus.

Corcept Therapeutics Incorporated (NASDAQ:CORT) engages in the discovery and development of medications for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

While we acknowledge the potential of CWAN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CWAN and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 14 Best US Stocks to Buy for Long Term

Disclosure: None.